Path BioAnalytics, Recce Pharmaceuticals Collaborate to Test Novel Drug Candidates for SARS-CoV-2

Raymond Young

I am Raymond Young and I’m passionate about business and finance news with over 4 years in the industry starting as a writer working my way up into senior positions.

I am the driving force behind Import Tourism with a vision to broaden the company’s readership throughout 2016. I am an editor and reporter of “Technology” category.

Address: 3194 Flynn Street, Garfield Heights, OH 44125, USA
Phone: (+1) 440-829-5759
Email: raymondyoung@importtourism.com
Raymond Young

In a pioneering development in pharmaceutical industry which is currently investing significantly towards tackling the sudden spurt of corona virus rendered pandemic, is routinely witnessing high profile business ventures and corporate engagement to adequately address, identify and develop novel therapeutic and diagnostic practices to optimally control the relentless spread of the virus, besides addressing the fatality associated with the same.
In these similar notes, it’s vital to know about the most recent pharmaceutical venture and development, marking the collaborative efforts of Recce Pharmaceuticals and Path BioAnalytics.
The companies have joined forces to minutely study the impact and efficacy of two of Recce Pharmaceuticals drug candidates such as Recce 529 and Recce 327 against SARS-CoV-2.
The collaboration is speculated to effectively study, assess and evaluate these probable compounds that are touted to offset the implications and infection triggered by SARS-CoV-2.
Path BioAnalytics is a frontline pharmaceutical veteran dedicated towards development of high-end precision drugs for chronic and rare disease management.
The company is located at North Carolina in the US and is highly renowned for its proprietary respiratory therapeutic technology such as organoid technology.
This technology, as part of the recent collaboration is poised to allow Recce Pharmaceuticals to use the flagship organoid technology to assess the efficacy of the above mentioned drug candidates for the treatment of SARS-CoV-2.
Path BioAnalytics’ proprietary organoid technology encompass pseudo-stratified respiratory organoids and 3D cell cultures which are sourced from primary respiratory cells. The company is committed to test the efficacy of the aforementioned Recce drugs in a respiratory organoid ecosystem.
Of the two candidates, Recce 327 is a synthetic antibiotic compound directed for treating infections in the blood as well as sepsis. The other compound is a synthetic polymer combination with surged anti-infection capabilities.

Raymond Young

Raymond Young

I am Raymond Young and I’m passionate about business and finance news with over 4 years in the industry starting as a writer working my way up into senior positions. I am the driving force behind Import Tourism with a vision to broaden the company’s readership throughout 2016. I am an editor and reporter of “Technology” category. Address: 3194 Flynn Street, Garfield Heights, OH 44125, USA Phone: (+1) 440-829-5759 Email: raymondyoung@importtourism.com